For two decades, drug production concentrated overseas. That's reversing. Drug shortages, supply-chain fragility, and a wave of policy on both sides of the Atlantic are pushing medicine manufacturing back home — and closer to the patient. But local production only works if the operational software behind it is affordable and quick to stand up. That's exactly the gap Pharmacy Flow fills.
The policy momentum is real — on both sides of the Atlantic
Drug-shortage pressure, moves to de-risk from foreign contract manufacturers, tariffs on pharma imports, and FDA advanced-manufacturing incentives are all pushing production onshore.
The Critical Medicines Act and the drive for medicine strategic autonomy are incentivizing EU-local API and generic manufacturing to cut dependency on distant suppliers.
Categories like compounded GLP-1s showed how fast local demand can outrun capacity — creating urgent need for new, nimble domestic production.
The catch: local only works if it's affordable to operate
What local manufacturers get out of the box
- ✓cGMP-ready batch manufacturing with component lot capture and reconciliation
- ✓Unit-level serialization and one-click recall for full traceability
- ✓A built-in quality system — deviations, CAPA, change control, environmental monitoring — with 21 CFR Part 11 e-signatures
- ✓DEA, state-licensure, USP <797>/<800>, and cold-chain controls enforced in the workflow
- ✓Fulfillment automation that scales output across people and machines
- ✓Digital order intake so distributed sites plug into telehealth and B2B demand instantly